-
1
Expanded Use of Vorasidenib in Non-Enhancing Recurrent CNS WHO Grade 3 Oligodendroglioma
Published 2025-01-01Subjects: Get full text
Article -
2
Safety profiles of IDH inhibitors: a pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS) database
Published 2025-02-01Subjects: “…IDH inhibitors…”
Get full text
Article